Last year was, well, not the greatest for the drug industry.
A contentious presidential election where both candidates slammed the biopharma industry, with a healthy assist from a cast of cartoonish, price-gouging villains, marred the entire sector (the NASDAQ Biotech Index fell some 20% over the course of the year). And that also had an effect on dealmaking, with a dearth of health care “megadeals” and a retrenchment in overall deal value, according to a new analysis by analytics firm Evaluate’s EP Vantage arm.
